Combination Therapy in Pulmonary Arterial Hypertension

Inclusion Criteria

• •1. Signed informed consent prior to initiation of any study-mandated procedures.
• •2. Males or females ≥ 12 years of age (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception).
• •3. Symptomatic patients with the following types of PAH belonging to World Health Organization (WHO) Pulmonary Hypertension Classification Group I:
• •* Idiopathic (IPAH)
• •* Familial (FPAH)
• •* Associated with PAH (APAH):
• •* Collagen vascular disease
• •* Drugs and toxins
• •4. Patients naïve to treatment with advanced PAH therapies (i.e., endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors or prostacyclins) with a right heart catheterization (RHC) showing all of the following:
• •* Mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg
• •* Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg or left ventricular end diastolic pressure (LVEDP) ≤ 15 mm Hg when PCWP is not accurately obtained
• •* Pulmonary vascular resistance ≥ 3 Wood units
• •5. 6-MWT distance ≥ 150 meters and \< 360 meters.
• •3. Pregnant and/or nursing.
• •4. Women of childbearing potential not using a reliable method of contraception.
• •5. Patients with known human immunodeficiency virus (HIV) infection.
• •6. Patients with significant vasoreactivity during right heart catheterization (i.e., a fall in mPAP to \< 40 mm Hg with a decrease of ≥ 10 mm Hg and with a normal cardiac index ≥ 2.5 l/min.m\^2).
• •7. Patients with restrictive lung disease (i.e., total lung capacity (TLC) \< 60% of normal predicted value).
• •8. Patients with obstructive lung disease (i.e., forced expiratory volume/ forced vital capacity (FEV1/FVC) \< 0.5).
• •9. Patients with impaired left ventricular function (LVEF \<50%) or diastolic dysfunction.
• •10. Patients with portal hypertension, cirrhosis, moderate to severe liver impairment (Child-Pugh Class B or C), or liver enzymes (Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) \> 3.0 times the upper limit of normal range.
• •11. Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) sirolimus, everolimus up to 1 week prior to Baseline (Day 1).
• •12. Patients currently receiving or predicted to require treatment, during the course of the study, with nitrates, protease inhibitors, or alpha-blockers.
• •13. Patients with a hemoglobin concentration \< 75 % of the lower limit of the normal range or \< 8.5 g/dL.
• •14. Patients currently receiving or predicted to require treatment with a prostanoid during the course of the study.
• •15. Patients with systolic blood pressure \< 85 mm Hg.
• •16. Patients with body weight \< 40 kg.
• •17. Patients who have received any investigational product within 90 days prior to Baseline.
• •18. Patients who previously received any advanced therapy for PAH (e.g., ERAs, PDE-5 inhibitors or prostacyclins).
• •19. Patients with hypersensitivity to sildenafil or any excipients of its formulation.
• •20. Patients with any contraindication to sildenafil treatment (i.e., nitrates).
• •21. Patients with any recent medical condition limiting the ability to comply with the study requirements (i.e., stroke, myocardial infarction).
• •22. Patients with unstable PAH whose disease state would prohibit the completion of study procedures, in the opinion of the investigator.
• •23. Patients unable to complete a MRI scan (e.g., claustrophobia).
• •24. Patients with permanent cardiac pacemakers, automatic internal cardioverter defibrillators (AICD's), neurostimulators, hearing aides, and other implanted metallic devices that are contraindicated during a MRI study.
• •25. Patients with conditions that would interfere with proper cardiac gating during MRI, such as atrial fibrillation or multiple premature ventricular contractions (PVCs)/premature atrial contractions (PACs).
• •26. Patients with conditions that prevent compliance with the protocol or the ability to adhere to therapy.